Sunday, May 19, 2024
English English French Spanish Italian Korean Japanese Russian Hindi Chinese (Simplified)


Viridian Therapeutics is a biopharmaceutical firm committed to creating best-in-class medicines for rare and serious illnesses, specifically where existing treatments fall short. The company’s lead program, VRDN-001, a monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R), targets


* indicates required

The Enterprise is an online business news portal that offers extensive reportage of corporate, economic, financial, market, and technology news from around the world. Visit to explore daily national, international & business news, track market movements, and read succinct coverage of significant events. The Enterprise is also your reach vehicle to connect with, and read about senior business executives.

Address: 150th Ct NE, Redmond, WA 98052-4166

©2024 The Enterprise – All Right Reserved.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept